GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

HeartSciences HSCS · USD

Health Care · US listing · 🇺🇸 United States

Compare

2.71

-4.24%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2026

Revenue

$4,319

FY2020FY2026

Net income

−$9.1m

FY2020FY2026

Free cash flow

−$7.5m

FY2020FY2026

Shareholders' equity

$225.5m

FY2020FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Revenue$4,319$4,350$18,600$5,150$14,373$25,604$64,182
Gross profit−$128,799−$125,485−$82,614−$24,561−$20,083−$18,672−$46,105
Research and development$2.84bn$4.4m$2.9m$2.5m$3.0m$1.7m$2.0m
Operating income−$16.4m−$8.4m−$6.3m−$6.1m−$4.5m−$2.6m−$3.8m
Net income−$9.1m−$8.8m−$6.6m−$6.4m−$4.8m−$2.5m−$3.8m
Diluted earnings per share-2.49-3.15-7.20-58.08-58.81-74.08-1.04

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Total assets$5.26bn$4.2m$9.5m$3.3m$2.1m$1.9m$2.0m
Cash and short-term investments$1.66bn$1.1m$5.8m$1.7m$918,260$723,481$496,853
Total liabilities$5.04bn$4.0m$2.2m$3.1m$8.1m$3.8m$1.6m
Debt$3.94bn$3.0m$1.0m$1.6m$6.2m$3.1m$942,710
Shareholders' equity$225.5m$205,171$7.3m$230,557−$6.1m−$1.9m$315,551
Shares outstanding4m3m1m0m0m0m4m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations−$7.4m−$7.4m−$6.1m−$5.8m−$3.6m−$2.5m−$3.8m
Capital spending−$44,452−$30,188−$125,271−$18,308−$1,932−$712−$11,424
Free cash flow−$7.5m−$7.4m−$6.2m−$5.8m−$3.6m−$2.5m−$3.9m

Latest quarters

By quarter end

Jul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024
Revenue$2,100$89.5m—$2,419$1,900$4,350——
Gross profit−$33,188$89.4m−$33,238−$31,024−$30,535−$28,791−$28,967−$34,410
Operating income−$2.9m−$2.5m−$1.9m−$2.1m−$1.9m−$1.9m−$2.4m−$2.0m
Net income−$3.2m−$2.8m−$2.0m−$2.4m−$2.1m−$2.1m−$2.5m−$2.1m
Diluted earnings per share-0.86-0.75-0.54-0.85-0.74-0.75-0.91-2.27
Cash from operations−$1.32bn−$1.0m−$1.0m−$2.0m−$1.0m−$1.0m−$1.0m−$2.0m
Capital spending—−$19.0m——————
Free cash flow—−$20.0m——————
Total assets$3.7m$5.3m$7.6m$6.0m$6.4m$4.2m$5.7m$7.8m
Cash and short-term investments$29.9m$1.66bn$3.40bn$2.0m$2.8m$1.1m$2.6m$4.1m
Debt$3.9m$3.8m$3.7m$628,977$1.7m$2.7m$2.6m$2.5m
Shareholders' equity−$2.0m$226,060$2.7m$4.2m$3.1m$205,171$1.8m$4.0m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-5.7%-29.9%—
Operating income38.8%44.8%—
Net income12.9%30.1%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin-2933.3%-1115.0%-552.8%—
Operating margin-285056.8%-114358.3%-60913.0%—
Net margin-206564.8%-95211.5%-52692.2%—

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022
Price to earnings-1.2-1.0-0.5-0.2-0.6
Price to sales——188.4224.1187.6

Share price return

Finished calendar years

2025202420232022
Return-42%-63%-71%-63%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 100-to-1 reverse split · 17 May 2024

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.